Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
Peter G PappasJose A VazquezIlana OrenGalia RahavMickael AounPierre BulpaRonen Ben-AmiRicard FerrerTodd MccartyGeorge R Thompson IiiHaran SchlammPaul A BienSara H BarbatPamela WedelIwona OborskaMargaret TawadrousMichael R HodgesPublished in: The Journal of antimicrobial chemotherapy (2023)
Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.
Keyphrases